46 results about "Albumin nanoparticles" patented technology

The invention relates to a CD44 receptor and scavenger receptor-A (SR-A) dual-targeting pharmaceutical composition as well as a preparation method and application thereof. According to the invention, a certain proportion of carrier material with CD44 receptor targeting capability is adsorbed on the fatty acid albumin nanoparticles, and the albumin nanoparticles with CD44 receptor and SR-A dual-targeting capability are successfully prepared. The albumin nanoparticles can simultaneously deliver drugs to activated macrophages with high SR-A specificity expression and fibroblasts or tumor cells with high CD44 receptor specificity expression, provide new treatment schemes and ideas for various diseases including tissue fibrosis and tumors, and have great application value in the field of biological medicine.

The invention discloses a pH-responsive deformable dual-targeting nano protein and a preparation method and application thereof, the method comprises the following steps: activating carboxylated mannose through an EDC / NHS system, reacting with an albumin solution, and dialyzing and purifying to obtain mannose modified albumin; and mixing the mannose modified albumin with an inhibitor IRG1-IN-1, and loading the IRG1-IN-1 through a hydrophobic effect to obtain the mannose albumin nanoparticles, ferritin serves as a carrier, oxaliplatin is loaded through a solvent replacement method, and ferritin nanoparticles are obtained; cHO-PEG2k-CHO is used as a coupling agent, and the mannose albumin nanoparticles and the ferritin nanoparticles are crosslinked through a Schiff base reaction, so that the large-size pH-responsive dual-targeting nano-protein is formed. The nano protein has the characteristic of double-targeting separability, so that specific treatment can be realized, immune cell metabolism is interfered while tumor cells are killed, metabolic immunosuppression is blocked, and anti-tumor immunotherapy is promoted.

The invention relates to the technical field of biological medicines, and discloses hyaluronic acid modified metal coordination albumin nanoparticles as well as a preparation method and application thereof. The hyaluronic acid modified metal coordination albumin nanoparticle comprises a core and a hyaluronic acid shell layer, wherein the core is formed by self-assembly of an albumin-drug compound, poly-L-aspartic acid and ferric ions through coordination, and the hyaluronic acid shell layer is connected to the surface of the core through coordination or adsorption. According to the hyaluronic acid modified metal coordination albumin nanoparticles as well as the preparation method and the application thereof, the preparation method is simple, convenient and rapid, does not need complex covalent modification, is mild in condition and is easy for large-scale production, and the prepared nanoparticles are uniform in particle size, good in stability and high in stability. In addition, due to the fact that the hyaluronic acid is modified on the surface, the active targeting capacity on CD44 receptor high-expression tumor cells is achieved, the enrichment and treatment effects of the medicine on the tumor site are remarkably improved, and the application prospect in preparation of the anti-tumor medicine is wide.

The present application belongs to the technical field of medicine, and particularly relates to albumin nanoparticles co-loading paclitaxel and BMS-202, a preparation method and application thereof. The present application comprises a carrier and a delivery carrier loaded with drugs; comprises a carrier and drugs loaded by a delivery carrier; the drugs are paclitaxel and an inhibitor BMS-202 co-loaded with paclitaxel, and the delivery carrier is human serum albumin. The present application comprises the following steps: step 1: paclitaxel and the inhibitor BMS-202 are dissolved in an organic solvent as an organic phase; step 2: human serum albumin is dissolved in water as an aqueous phase; step 3: the organic phase is directly added to the aqueous phase, and after mixing, ultrasonic treatment is immediately performed to make the system form a nanoparticle suspension; step 4: the nanoparticle suspension is subjected to purification treatment to remove the organic solvent and unencapsulated drugs, and albumin nanoparticles co-loading paclitaxel and BMS-202 are obtained. The present application is applied to the preparation of esophageal squamous cell carcinoma drugs. Compared with the prior art, the present application is relatively effective and safe in the treatment of esophageal cancer.

The invention discloses a process for synergistically inhibiting melanoma by carrying low-dose paclitaxel on nanoparticles based on immunoregulation. According to the invention, hyaluronic acid functionalized albumin nanoparticles are combined with low-dose paclitaxel, the tumor targeting property of the drug is improved by utilizing a nanotechnology, and meanwhile, the tumor immune microenvironment is regulated and the anti-tumor immune effect is enhanced by activating an STING pathway. Through the combination, the treatment effect of the medicine is improved, the side effect of the medicine is remarkably reduced, and a new strategy is provided for tumor treatment. High-efficiency delivery of low-dose paclitaxel is realized through the nano-carrier, the drug dosage is reduced, the toxicity is reduced, meanwhile, the antitumor activity of the paclitaxel is retained, a new thought is provided for clinical application of traditional chemotherapeutic drugs, the tolerance and life quality of patients are expected to be improved, polarization of M1 type macrophages is promoted by activating an STING pathway, and the antitumor activity of the paclitaxel is improved. Interferon and other inflammatory factors are released, CD8 + T cells are recruited and activated, and therefore the anti-tumor effect is achieved.

The invention discloses glycyrrhetinic acid albumin nanoparticles. The glycyrrhetinic acid albumin nanoparticles are in a uniform spherical shape; the nanoparticles comprise glycyrrhetinic acid and albumin; the particle size of the nanoparticles is smaller than or equal to 200 nm, the encapsulation efficiency is 90%-95.10%, the drug loading capacity is 30.56%-63.40%, and glycyrrhetinic acid released by the nanoparticles within 24 hours is 60%-70%. The invention further discloses a preparation method of the glycyrrhetinic acid albumin nanoparticles, the nanoparticles obtained through the method are small in particle size and uniform in distribution, and the stability and safety of the nanoparticles are improved along with increase of the proportion of albumin; wherein the albumin-rich nanoparticles show dual-mode pharmacological activity in experiments for preventing and treating acute liver injury.

The invention relates to a cathepsin B sensitive fatty acid-adriamycin prodrug as well as albumin nanoparticles, a preparation method and application thereof, and belongs to the technical field of medicines. The cathepsin B sensitive fatty acid-adriamycin prodrug is a prodrug as shown in a formula (I), a geometric isomer thereof, and pharmaceutically acceptable salts, hydrates and solvates thereof, wherein n is equal to 0-14. The invention also relates to a combined albumin nanoparticle prepared by entrapping the cathepsin B sensitive fatty acid-adriamycin prodrug by using human / bovine serum albumin as a carrier. The albumin nanoparticles are small in particle size and uniform in form, have good placement stability and colloidal stability, can stably exist in systemic circulation and normal tissues, and release a parent drug adriamycin after being taken by tumor cells and hydrolyzed by cathepsin B; therefore, specific killing of tumor cells is realized without generation of serious toxic and side effects, and good clinical development prospects are achieved.

The embodiment of the present application proposes a preparation method of albumin nanoparticles and its use. The preparation method comprises: dissolving albumin in water to obtain an albumin solution; adding ethanol to the albumin solution to obtain a mixed solution; heating and stirring the mixed solution to obtain a supernatant, and dehydrating the supernatant to obtain albumin nanoparticles. The preparation method of the albumin nanoparticles provided in the embodiment of the present application adopts ultrapure water to dissolve the albumin, and adds ethanol to the albumin solution to destroy the hydration layer on the surface of the albumin, and forms a gel-like structure of the albumin by heating. At the same time, the stirring shear force and the cavitation effect of the gas and ethanol vapor in the water cause the albumin to break and polymerize to form nanoparticles. Therefore, the preparation method of the embodiment of the present application not only shortens the time for nanoparticle formation, but also reduces the amount of organic solvent used and simplifies the process, that is, albumin nanoparticles with low particle size and uniform particle size distribution can be obtained.

The present invention relates to the technical field of eye medical products, and in particular to a protein eye protection liquid and a preparation process thereof. The preparation process comprises the following steps: preparing albumin nanoparticles; preparing astragalus glycoside; preparing astragalus glycoside nano-albumin; and preparing astragalus glycoside nano-albumin eye drops. The present invention couples albumin nanoparticles with astragalus glycoside, and uses nanoparticles to coat astragalus glycoside, thereby reducing the irritation of astragalus glycoside. Moreover, the astragalus glycoside coated with nanoparticles can prevent astragalus glycoside from aggregating in the eye protection liquid, thereby ensuring the stability and dispersibility of the eye protection liquid, and is slowly released in the eye protection liquid, thereby ensuring the stability of the astragalus glycoside efficacy, and being more gentle, thereby achieving the effect of eye protection.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to manganese-based paclitaxel albumin nanoparticles as well as a preparation method and application thereof. The preparation method comprises the following steps: S1, adding paclitaxel into absolute ethyl alcohol to form a paclitaxel-ethyl alcohol mixture with the concentration of 1mg / mL; s2, adding PEG (Polyethylene Glycol) into the paclitaxel-ethanol mixture, carrying out vortex mixing uniformly, and removing an organic solvent in the paclitaxel-ethanol mixture through rotary evaporation to obtain a mixed solution of paclitaxel and PEG; s3, adding HSA into the mixed solution of the paclitaxel and the PEG to enable the mixed solution not to be in a flowing state, so as to obtain a semi-solid mixture of the paclitaxel and the PEG; and S3, adding a KMnO4 solution into the semi-solid mixture obtained by mixing paclitaxel and PEG, uniformly mixing, and then carrying out ultrasonic treatment to obtain the manganese-based paclitaxel albumin nanoparticles (PTX-HSA-MnO2NPs). And the preparation process can meet the requirements of green industrial production.

This invention provides a method for the continuous preparation of paclitaxel albumin nanoparticles, comprising the following steps: A) Paclitaxel raw material is fed into an emulsification device at a first rate of 80-90 ml / min; albumin aqueous solution is fed into the emulsification device at a second rate of 3-4 L / min; B) Paclitaxel raw material and albumin aqueous solution are emulsified and sheared to complete drug loading, thus obtaining the nanoparticles. In this method, the paclitaxel organic solvent and human serum albumin aqueous solution are continuously introduced, allowing for continuous emulsification and shearing. The emulsification and shearing effect is consistent every minute, and the production batch size is only related to time. The batch size is determined by controlling the emulsification and shearing time, and the product uniformity is not affected by the batch size. This invention solves the problem that current paclitaxel nanoparticle preparation processes cannot achieve continuous manufacturing, improving system flexibility; and addresses the problems of batch dependence on equipment and difficulty in batch expansion.

The invention belongs to the technical field of medicines, and relates to Torin 1 albumin nanoparticles attached to the surfaces of red blood cells, a preparation method of the Torin 1 albumin nanoparticles and application of the Torin 1 albumin nanoparticles in acute lung injury. The preparation method comprises the following steps: self-assembling an indissolvable mTOR kinase inhibitor Torin1 and bovine serum albumin to form drug-loaded nanoparticles, homogenizing the drug-loaded nanoparticles, and attaching the drug-loaded nanoparticles to the surfaces of red blood cells to obtain RBC-Torin1-coated BSA. The system can improve the problem of poor solubility of Torin1, reduce nonspecific removal of nano-particles, improve distribution and enrichment of the nano-particles in lung tissues, and enhance the treatment effect on acute lung injury.

The invention discloses a preparation process of docetaxel albumin nanoparticles, and belongs to the technical field of biological medicine preparation, the key point of the technical scheme is that the preparation process of the docetaxel albumin nanoparticles comprises the following preparation steps: S1, dissolving docetaxel in an organic solvent; s2, controlling the pH value of the aqueous solution containing arginine in a range of 4-6; s3, adding albumin into the arginine aqueous solution obtained in the step S2, and performing low-temperature shearing to obtain an albumin arginine aqueous solution; s4, reacting the albumin arginine aqueous solution obtained in the step S3 with the mixture obtained in the step S1 to obtain a reaction solution; and S5, carrying out high-pressure homogenization on the reaction liquid to obtain the docetaxel albumin nanoparticles. The docetaxel albumin nanoparticles obtained by taking arginine as a developing solvent of albumin are completely stable within 5 hours, the stability exceeds 24 hours when the docetaxel albumin nanoparticles are stored at 4 DEG C, and the phenomenon of precipitation or precipitation does not occur.

The present disclosure provides a protein-based nanoparticle made of a protein and an amine for the delivery of a nucleic acid molecule, such as an mRNA vaccine, to a cell. The present disclosure further provides systems and methods for producing such protein-based nanoparticle including a nucleic acid molecule, and methods of delivering the nucleic acid molecule to a cell, and treating a subject with the compositions as disclosure herein.

The invention discloses preparation and application of a metal-polyphenol modified albumin nano-drug, and belongs to the field of medicines.The preparation method comprises the steps that 1, IR780 dissolved in absolute ethyl alcohol is added into an albumin aqueous solution under magnetic stirring, absolute ethyl alcohol continues to be dropwise added, and albumin wraps IR780 to be separated out to form nanoparticles; and (2) adding a proper amount of glutaraldehyde cross-linked albumin to obtain the stable IR780-loaded albumin nanoparticles. And (3) in an alkaline environment, tannic acid and Mn < 2 + > with proper concentration are introduced into the IR780-loaded albumin nanoparticles, so that a complex is formed to cover the surfaces of the albumin nanoparticles, and the final preparation of the nanoparticles is completed. According to the invention, the IR780-loaded albumin nanoparticles are modified by a metal-polyphenol network, so that the nano-drug has the capability of co-delivering a photosensitizer and metal manganese ions to a tumor site at the same time. The medicine has good effects in the aspects of treating superficial tumors, inducing tumor immunogenic cell death, promoting antigen presentation, enhancing anti-tumor immune response and the like.

The application belongs to the technical field of biological medicine material preparation, and particularly relates to albumin nanoparticles loaded with ferroptosis related drugs and a preparation method thereof. The ferroptosis related drug composition comprises porphyrin drugs, unsaturated fatty acid drugs-cystamine and sulfosuccinimidyl oleate (SSO). The porphyrin drugs, the unsaturated fatty acid drugs-cystamine and the SSO are slowly added dropwise into an albumin solution under stirring, the drugs enter the hydrophobic cavities of the albumin, and uniform nanoparticles are spontaneously formed. The obtained nanoparticles are small in size and uniform, can efficiently deliver drugs through passive targeting mediated by the EPR effect and active targeting mediated by the Gp60-Caveola-SPARC pathway, improve stability, reduce accumulation at non-target sites and systemic toxicity, amplify the effect of ferroptosis after combination compared with the ferroptosis related drugs used alone, and thus produce a synergistic anti-tumor effect.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to human serum albumin nanoparticles entrapped with alpha-mangostin as well as a preparation method and application of the human serum albumin nanoparticles. The alpha-M entrapped human serum albumin nanoparticles provided by the invention comprise an alpha-M raw material medicine and human serum albumin (HSA), the preparation method comprises the following four steps: high-pressure homogenization, rotary evaporation, degerming filtration and freeze drying. The nano delivery system has good safety and stability, and is proved to have multiple effects of immunoregulation, tumor invasion and metastasis inhibition, matrix barrier weakening and the like at cellular level and animal level; the compound can be used for preparing anti-tumor drugs including pancreatic cancer, breast cancer, colon cancer and the like, can be used for effectively inhibiting tumor progression when being combined with chemotherapy drugs, and has broad-spectrum anti-cancer application value.

This invention relates to a cathepsin B-sensitive fatty acid-doxacin prodrug, its albumin nanoparticles, preparation method, and application, belonging to the field of pharmaceutical technology. The cathepsin B-sensitive fatty acid-doxacin prodrug is defined as the prodrug shown in general structural formula (I), its geometric isomers, and its pharmaceutically acceptable salts, hydrates, and solvates; where n = 0-14. Further, the cathepsin B-sensitive fatty acid-doxacin prodrug is encapsulated using human / bovine serum albumin as a carrier to prepare bound albumin nanoparticles. These albumin nanoparticles have a small and uniform particle size, exhibiting good placement and colloidal stability. They remain stable in systemic circulation and normal tissues. However, after being taken up by tumor cells, they are hydrolyzed by cathepsin B to release the parent drug doxacin, thereby achieving specific killing of tumor cells without producing serious toxic side effects, showing promising clinical development prospects.

The invention relates to a CES1 / CES2 cascade activated camptothecin-fatty alcohol prodrug and albumin nanoparticles thereof as well as a preparation method and application thereof, and belongs to the technical field of medicines. The CES1 / CES2 cascade activated camptothecin-fatty alcohol prodrug is a prodrug as shown in a formula (I) or a pharmaceutically acceptable salt of the prodrug. The invention also relates to a combined albumin nanoparticle prepared from the camptothecin-fatty alcohol prodrug entrapped with CES1 / CES2 cascade activation. The albumin nanoparticles are small in particle size and uniform in form, have good placement stability and colloidal stability, can stably exist in systemic circulation and normal tissues, can release an intermediate through CES1-mediated primary hydrolysis after being taken by tumor cells, and then the intermediate is subjected to secondary hydrolysis under the action of CES2 to release a parent drug camptothecin, so that the curative effect of the camptothecin on tumor cells is improved, and the curative effect of the camptothecin on tumor cells is improved. Therefore, specific killing of tumor cells is realized without generation of serious toxic and side effects, and good clinical development prospects are achieved. Formula (I)

This invention provides a biomimetic nanoparticle composite PRP hydrogel with anti-fibrotic and anti-inflammatory functions, its preparation method, and its application. The biomimetic nanoparticle composite PRP hydrogel is formed by cross-linking a hydrogel matrix and composite nanoparticles dispersed therein. The core of the composite nanoparticles is albumin nanoparticles loaded with macrophage migration inhibitory factor inhibitors, and the outer shell of the composite nanoparticles is a fibroblast membrane. The preparation method includes the following steps: preparing a composite nanoparticle dispersion; mixing sodium alginate with the composite nanoparticle dispersion to prepare a sodium alginate solution; adding platelet-rich plasma and mixing evenly; adding calcium carbonate and an acidity regulator; stirring evenly and allowing to stand to form a gel, thus obtaining the biomimetic nanoparticle composite PRP hydrogel with anti-fibrotic and anti-inflammatory functions.

The invention relates to a preparation method and application of oxaliplatin albumin nanoparticles, and the preparation method comprises the following steps: S1, reacting a dichloro (1, 2-diaminocyclohexane) platinum (II) solution with a silver nitrate solution, removing precipitate to obtain an oxaliplatin precursor ion solution, adding a sodium chloride solution, standing, and filtering to obtain a purified oxaliplatin precursor ion solution; and S2, mixing the purified oxaliplatin precursor ion solution with an albumin aqueous solution, adjusting the pH value to 4.5-5.5, adding a potassium oxalate solution to obtain a mixed solution, carrying out a stirring reaction, and carrying out ultrafiltration purification for a plurality of times to obtain the oxaliplatin albumin nanoparticles. According to the oxaliplatin albumin nanoparticle and the preparation method thereof, a quality controllable method is established by improving a preparation process and optimizing parameters, the oxaliplatin albumin nanoparticle which is low in impurity content, high in proportion of oxaliplatin in total platinum and high in encapsulation efficiency is prepared, a better treatment effect is shown in the aspect of tumor combined treatment, and the clinical application potential of oxaliplatin is improved.

The present application belongs to the technical field of biological medicine, and particularly relates to a sodium alginate microsphere co-loading nano-gold probiotics and curcumin albumin nanoparticles and preparation and application thereof. The present application synthesizes nano-gold by modifying probiotics Escherichia coli Nissle 1917, prepares curcumin albumin nanoparticles by using the principle of self-assembly, and then prepares the sodium alginate microsphere co-loading nano-gold probiotics and curcumin albumin nanoparticles by using the method of high-voltage electrostatic, which is used for the treatment of inflammatory bowel disease. Compared with the traditional preparation of nano-gold, the present application proposes a new green synthesis method, while keeping the activity of probiotics. In order to improve the problem of poor water solubility of curcumin, the present application uses albumin to load drugs, prepares curcumin albumin nanoparticles, and then combines with the sodium alginate microsphere, which has colon targeting, improves the bioavailability of probiotics and curcumin, and is effectively used for the treatment of inflammatory bowel disease.

This invention discloses albumin nanoparticles co-loaded with flavin and lactate oxidase, their preparation method, and applications. Using human serum albumin as a carrier, flavin and lactate oxidase are simultaneously encapsulated at a mass ratio of 10:1, with a particle size of 150-180 nm and a polydispersity index of less than 0.2. This invention exerts its anti-hepatocellular carcinoma effect through mechanisms such as reducing lactate levels in the tumor microenvironment, inducing an increase in reactive oxygen species, inhibiting cGAS protein lactation modification, and activating the cGAS-STING signaling pathway. The nanoparticles exhibit high encapsulation efficiency and good stability. The flavin loaded on these nanoparticles can significantly reduce the reduction of pyruvate to lactate by inhibiting lactate dehydrogenase; simultaneously, the lactate oxidase loaded on these nanoparticles catalyzes the dehydrogenation of lactate to pyruvate. In other words, these nanoparticles synergistically regulate lactate metabolism through a two-way regulatory strategy of "reducing source and increasing sink"—"inhibiting lactate production" and "promoting lactate clearance"—significantly enhancing in vitro and in vivo anti-tumor effects, and demonstrating high biosafety.

The invention discloses a method for improving the particle size stability of drug-loaded albumin nanoparticles. The method for improving the particle size stability of the drug-loaded albumin nanoparticles comprises the step of sealing sulfydryl-SH on the surfaces of the drug-loaded albumin nanoparticles. The problem that the particle size of the drug-loaded albumin nanoparticles is increased due to the placement process can be effectively solved.

The invention provides an ROS responsive R848 prodrug as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The active oxygen responsive R848 prodrug comprises R848, a maleimide group and an active oxygen responsive thioketal bond connecting the R848 and the maleimide group, the prodrug can be coupled to an albumin molecule through the design, then the prodrug and a photosensitizer Ce6 are self-assembled to form albumin nanoparticles, and after the nanoparticles reach a tumor site, the nanoparticles are self-assembled to form the albumin nanoparticles. When laser irradiates a tumor site, high-concentration active oxygen is locally generated through a photosensitizer to kill tumor cells, meanwhile, active oxygen responsive chemical bonds are broken to release R848 to act on immune cells of the tumor site, photodynamic therapy and immunotherapy are achieved, anti-tumor activity is shown, and the compound has important significance on tumor combined therapy.

The invention discloses a preparation method of gold (I) albumin nanoparticles and application of the gold (I) albumin nanoparticles in antitumor activity. Belongs to the field of medicine, and the preparation method comprises the following steps: dissolving BSA in ultrapure water, titrating with N sodium hydroxide until the pH value is 8.5, dropwise adding an ethanol solution of a gold (I) compound, dropwise adding absolute ethyl alcohol, adding 8% glutaraldehyde, stirring, removing the free gold (I) compound and ethanol through dialysis, centrifuging for three times to obtain purified nano-particles, and drying to obtain the gold (I) compound. And freeze-drying to obtain the nanoparticle freeze-dried powder. According to the invention, the input ratio of BSA to the gold (I) compound is determined through preparation of the nanoparticles, the characterization of TEP NPs shows that the particle size has good stability, and the release behavior is shown under the pH condition close to the tumor microenvironment. The result shows that the TEP NPs can retain most of the gold (I) compounds in the nanoparticles, and after the nanoparticles are accumulated at the tumor site through the ERP effect, a large amount of the gold (I) compounds are released to achieve the tumor cell killing effect of the nanoparticles.

The invention belongs to the technical field of pharmaceutical preparations, and provides an iRGD peptide modified cabazitaxel albumin nanoparticle (iRGD-HSA-CTX NPs) and a preparation method thereof, and the iRGD-HSA-CTX NPs is prepared from the following raw materials in parts by weight: 2.5 to 10 parts of cabazitaxel, 50 to 200 parts of albumin, 20 to 100 parts of phospholipid, 500 to 2000 parts of iRGD peptide, 1500 to 6000 parts of cross-linking agent and 0.005 to 0.3 part of freeze-drying protective agent. The iRGD-HSA-CTX NPs prepared by the preparation method disclosed by the invention is relatively small in particle size, uniform in particle size distribution and high in drug encapsulation efficiency, the toxic and side effects of CTX are reduced, the tumor targeting property is improved, and the anti-tumor activity is enhanced.

The application discloses a pH-responsive deformable double-targeting nano-protein and a preparation method and application thereof, and the method comprises the following steps: after carboxylated mannose is activated through an EDC / NHS system, the carboxylated mannose is reacted with an albumin solution, and mannose-modified albumin is obtained through dialysis purification; the mannose-modified albumin is mixed with an inhibitor IRG1-IN-1, and IRG1-IN-1 is loaded through hydrophobic interaction to obtain mannose albumin nanoparticles; ferritin is used as a carrier, and oxaliplatin is loaded through a solvent displacement method to obtain ferritin nanoparticles; CHO-PEG2k-CHO is used as a connecting agent, and the mannose albumin nanoparticles and the ferritin nanoparticles are crosslinked through a Schiff base reaction to form large-size pH-responsive double-targeting nano-proteins. The double-targeting separable characteristics of the nano-proteins can realize specific treatment, kill tumor cells, interfere with immune cell metabolism, block metabolic immunosuppression, and promote anti-tumor immunotherapy.

The invention belongs to the technical field of biological medicines, and particularly relates to NA1-albumin nanoparticles as well as a preparation method and application thereof. According to the preparation method disclosed by the invention, NA1 is encapsulated inside and on the surface of albumin nanoparticles through electrostatic interaction between Nerinetide (NA1) and the albumin nanoparticles, so that NA1-albumin nanoparticles are obtained. The encapsulation efficiency of the NA1-albumin nanoparticles to NA1 can reach 80-90%, and the NA1-albumin nanoparticles have the characteristics of natural degradation and pH responsive degradation. The albumin nanoparticles are swallowed by immune cells through complement conditioning, are delivered by using methods such as skull marrow or intracerebral injection, bypass a blood-brain barrier by using a brain marginal immune pathway, improve the delivery efficiency and targeting of NA1 in the brain, have significant effects on reducing the volume of a stroke ischemic region, the volume of an ischemic core region, encephaledema and encephalatrophy, and are suitable for clinical application. The pharmaceutical composition can be used for treating acute brain injury, especially acute ischemic cerebral apoplexy.

The invention discloses a bifunctional albumin nanoparticle, a preparation method, a pharmaceutical composition and application. The nanoparticle takes albumin as a carrier, the surface of the nanoparticle is modified with a macrocyclic ligand chelating agent chelated with gadolinium ions, and the nanoparticle is internally wrapped with a hydrophobic boron-containing compound. The bifunctional albumin nanoparticle has good T1 weighted magnetic resonance imaging capability, can be used for tracking distribution and enrichment of boron-containing drugs in vivo in real time, realizes collaborative application with a boron neutron capture therapy, and is beneficial to evaluation of a treatment window and improvement of treatment accuracy; the particle size is uniform, the zeta potential is stable, the drug loading capacity and the tissue penetrability are good, and targeted enrichment on tumor tissues is facilitated; according to the bifunctional albumin nano-particles, human serum albumin is preferably selected as a nano-particle carrier, so that the bifunctional albumin nano-particles have excellent biocompatibility and good in-vivo stability, are high in safety and are beneficial to clinical transformation.